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ABSTRACT 
The opioid crisis has negatively affected many people around the world, claiming many 
lives from overdoses, creating financial distress from loss of employment, and destroying family 
units. The opioid crisis has particularly taken a life toll in the United States, where over 63,000 
deaths have been reported in 2016 (CDC). The crisis in the United States gained increased 
attention when it began to affect young, white, wealthy individuals. Portugal and Spain, two 
additional developed Western countries, with a high proportion of Caucasian populations, but 
with a national health care system were selected for comparison. 
In response, all three countries have addressed their perspective crisis in subjective 
manners. Portugal has seen the best outcomes due to the steps they implemented to overcome 
their crisis, especially when compared to the United States and Spain. Portugal’s success 
resulted from a multidisciplinary approach, including a change in its cultural perspective on 
individuals who misuse drugs. Spain, unlike the United States, has had stagnant numbers of drug 
misusers, and overdose deaths within their population. Although the statistics are not increasing, 
they have also not decreased, as seen in Portugal. 
As an intervention and with further observation of Portugal’s successful changes, specific 
examples can be implemented in the United States for improvement. Barriers will exist when 
including aspects of Portugal’s model, but modifications can be applied to overcome them.  
 v 
The opioid crisis has had tremendous public health implications due to the significant 
number of individuals suffering from substance use disorder, increasing mortality rates resulting 
from opioid overdoses, and the impact across geographic and socioeconomic populations. 
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1.0  BACKGROUND ON THE OPIOID CRISIS 
Opium is contained in the bulb of the opium poppy, and is a highly addictive substance. 
Opioids are derived from the opium and have the ability to provide pain relief (Quinones). Most 
of these drugs are prescribed as pain medications, and are widespread across the United States; 
however, not all opioids are legal prescription drugs, they can be illicit substances as well. For 
instance, heroin is also an opium derivative, whose use is however not accepted in medical 
practice due to its high addiction potential. People who became dependent on opioids turned to 
heroin, because it was less expensive and they could still get high (Quinones). Each of these 
drugs, with their highly addictive properties produce a sense of euphoria to the human body. The 
body builds up a tolerance and dependence for the drug, so increasing doses are required to 
obtain the same effect (Quinones). The addictive behaviors are extremely difficult to overcome, 
and often cause painful withdrawal symptoms, in which the individual feels all of the pain they 
were trying to conquer (Quinones).  
Prescription opioid use is seen largely in the United States to treat pain. Before 1980s, the 
use of opioids was restricted to the treatment of cancer-related pain; however, in the 1980s, 
physicians began to use them to treat chronic pain (Quinones). In the mid-1990s, the United 
States began to consider pain as the fifth vital sign in addition to pulse, temperature, respiration 
rate, and blood pressure (Morone & Weiner). Although it was never officially made the fifth 
vital sign, because it is impossible to measure pain quantitatively, physicians started to prioritize 
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pain control, which lead to an increase in the use of prescription opioids. The mindset of pain 
being another vital sign likely drove physicians to view pain as a high priority that needed to be 
treated.  
Simultaneously, there have been an increase in overdose deaths reported. The United 
States has witnessed the opioid crisis affecting multiple age groups and multiple ethnicities. 
Between 1999-2014, people aged 25-54 years old showed the highest overdose statistics. At the 
start of this time frame, men showed the highest rates, but as of 2014, the gender differences are 
becoming more equal. Non-Hispanic whites, American Indians, and Alaskan Natives are among 
the highest ethnicities effected (CDC). There are endless stories of physicians overprescribing 
and not holistically treating patients. Physicians across the U.S overprescribe pain medications, 
with very inconsistent practices. Pain medications are being prescribed at higher dosages, with 
more days supplies per person, in 2015, when compared to data in the late 1990s (CDC).   
It took nearly 20 years for the addictive behaviors of opioids to gain significant attention 
in the U.S. Toward the end of the 2000-2010 period, individuals who were taking a specific 
narcotic, called Oxycontin, were commonly known to transition to heroin (Quinones).  Three out 
of four individuals abused prescription opioids before using heroin (CDC). Once the crisis was 
recognized, the Food and Drug Administration (FDA) began to mandate drug companies to 
provide educational information to practitioners on the addictive qualities of their drugs. 
Additionally, as addiction became further recognized, many companies also began to create 
drugs that were supposed to be unable to crush for injection (Quinones). Changing the compound 
of these drugs was to help avoid the misuse of these drugs.  
Comparatively, the United States has seen considerably higher overdose rates compared 
to other countries, though opioid misuse is being seen in Europe, among other places around the 
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world. Illicit drug overdoses are far from uniform among countries. Spain and Portugal, two 
developed, Western countries boarded by the Atlantic Ocean, both with National Health Care 
Systems and a population majority of Caucasian individuals, were selected to compare their 
interventions and outcomes. In 2016, the United States witnessed 13 deaths per 100,000, caused 
by overdoses (CDC). In 2015, Portugal reported 0.58 deaths per 100,000 (EMCDDA), and Spain 
witnessed 1.48 deaths per 100,000 in 2014 (EMCDDA).  
Each of the three countries have taken their own steps to decrease the occurrences of 
overdose deaths, and to prevent children and teens from becoming addicted to opioids and illicit 
drugs. Portugal was able to change both policies and the stigma that surround drug use. They 
have seen a voluntary uptake of people seeking treatment programs of all forms, and there has 
been a decrease in the number of young people misusing drugs.  Spain has been able to provide 
clean needle and syringe programs, safe injection spaces, and Naloxone dispensing for overdose 
cases. 
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2.0  DISCUSSION OF HEALTH SYSTEMS 
The United States, Portugal, and Spain have different health care systems with minimal 
overlap between the system in the US and those of Portugal and Spain. The United States has a 
multi-payer system that includes both private and public governmentally funded payers. Both 
Spain and Portugal have nationally funded health care systems, which cover all citizens, and 
provides a universal reporting system for all medical services. Although the United States spends 
the most amount on health care per capita, these expenditures do not translate into improved 
outcomes, since life expectancy is lowest among the three countries and prevalence of chronic 
diseases is higher. 
2.1 THE UNITED STATES 
The United States is the only country of the three presented that does not provide 
universal health insurance for all citizens. In the American view, the closest thing to universal 
health care for the entire population was the enactment of the Patient Protection and Affordable 
Care Act, often referred to as the ACA, or Obamacare, because every citizen is required to have 
health insurance under the enactment. The United States continues to have private hospitals, 
unlike those in Europe where the hospitals are public under each country’s National Health 
System. Private health insurance in the United States began in the 1940s as a result of World 
War II. Insurance was used as an incentive to attract possible employees into working for their 
companies (Emanual). Traditionally, providers and facilities are reimbursed on a fee-for-service 
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system. This financial misalignment between payers and providers lead to an exponential 
increase in health care costs over time. For instance, the Gross Domestic Product (GDP) in 1960 
was 5%, and today is nearly 20% for health care costs (CMS).  
Obamacare was implemented in 2010 under the Obama Administration, and is still in 
place today. The ACA included a variety of provisions. First, the ACA mandates health 
insurance coverage for all American citizens, through a state based exchange. If individuals 
chose not to gain coverage they are penalized with a fine. Under the ACA, insurance companies 
must offer coverage for individuals with preexisting health conditions. Dependents are able to 
stay on their parents’ or guardians’ insurance plan until the age of 26. Second, in a total of 33 
states the coverage of Medicaid was expanded to cover all families making below 133% of the 
poverty line. Before the implementation of the ACA, households making an annual income of 
below 138% of the federal poverty line were eligible for coverage (Wehby and Lyu).  Third, 
under the ACA, tax credits and subsidies are also offered for those who cannot afford insurance, 
but whose income is higher than the threshold to qualify for Medicaid coverage. The ACA also 
created a plan to close the Medicare Part D coverage gap phase over time.  When Medicare Part 
D was enacted, there were four benefit phases in Stand-Alone Prescription Drug Plans, including 
an annual deductible, an initial coverage phase, a coverage gap, and catastrophic coverage. 
Under the coverage gap, patients were fully responsible for drug costs. The cycle resets at the 
beginning of the calendar year (Kaplan and Zhang). The plan under the ACA is to close that gap, 
so patients would no longer be responsible for 100% of the cost of their medications. By 2020, 
patients will be responsible for only 25% of the cost during the coverage gap (Bonakdar and 
Cunnigham). 
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Private insurance works through premiums, deductibles, and copayments. Premiums are 
the initial payments from the consumer to the insurance company, also known as the payer. 
Deductibles are charged to the consumer at the beginning on the calendar year, and is a certain 
amount of money that one must pay before their insurance coverage begins. The amount spent 
towards the annual deductible resets every year, and is dependent on the specific health plan. 
Copayments are predetermined costs for a service or medication that the patient is responsible 
for paying out-of-pocket. They are paid by the consumer at the time of a healthcare intervention, 
like a physician visit or the cost of their prescription (Emanuel). The positive outlooks of the 
ACA include an increase in the number of covered citizens, and the switch from volume based to 
value based reimbursement payments for physicians. Prior to the ACA, physicians were paid on 
a fee-for-service system, which incentivized the overuse of health services and decreased the 
efficiency of the healthcare system. The ACA however created the implementation of several 
provider payment models based on value, where providers are paid based on the clinical 
outcomes and costs incurred by the population they serve. Some of the potential negative 
impacts of the ACA an increase in premiums (Pariser). Additionally, at implementation, because 
more people have insurance, more people began visiting physicians, increasing their workload 
(Pariser). 
Under the ACA, there are four publicly funded insurance options for those qualify: 
Medicaid, Medicare, dual Medicare/Medicaid eligibility, and Children’s Health Insurance 
Program, called CHIP. The U.S Government provides a single payer system for active military 
personnel, and veterans. Medicaid is the insurance coverage for poor individuals or families 
which may include, pregnant women at or below 133% of the poverty line, or disabled 
individuals. Families covered under Medicaid make a combined income of less than 133% of the 
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poverty line (Racine, et. al.). Dual membership eligibility between Medicaid and Medicare are 
from patients who are no longer working due to age, or disabled individuals, both of which fall 
below a percentage of the federal poverty line (Emanuel).   
CHIP, implemented in 1997, covers children of families who need financial assistance 
paying for health insurance, but whose income is above the eligibility threshold for Medicaid 
(Emmanuel). Families who earn up to 200% of the federal poverty level qualify for their children 
to be covered. Children who have any other insurance coverage are ineligible for CHIP coverage 
(Racine, et. al). The program was originally implemented for 10 years, and funded through 
grants. In 2007, CHIP was renewed under the ACA, to be funded through a match between states 
and federal government.  
Lastly, veterans in the United States are covered under the government, and receive a 
majority of their care at the Veterans Health Administration (VHA). VA insurance is quite 
similar to that of a national health system, but as previously stated, only covers active military 
personnel and veterans. This system hires their own providers, which give medical care to the 
consumers. The VA is an integrated system, since acts as the provider and payer for the covered 
population. Of the 22 million U.S veterans, only 8.9 receive health benefits from the VHA. The 
other portion of the veteran population uses private health insurance, or programs like Medicaid, 
because they either have not enrolled in the VA system, or they are ineligible (Chokshi & 
Sommers).  
 
The table below summarizes each the three federally funded programs and who is eligible: 
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Table 1: Three Main Governmentally Funded Programs 
Program Covered Individuals Cost Federal or State 
Implementation 
Medicare • Individuals 65 years + 
• Disabled, low income 
individuals of all ages 
• Renal Disease Patients 
• Medicare + Medicaid 
Dual Eligibility 
• $672.1 billion in 2016 
(CMS, 2016) 
• 3.6% of GDP (KFF, 
2015) 
• Federal 
Medicaid • Low income 
individuals and families 
• Low income pregnant 
women 
• Disabled individuals  
• $565.5 billion (CMS, 
2016) 
• 3.0% of GDP (KFF, 
2015) 
• State 
CHIP • Children with no 
insurance coverage 
from families that make 
excess income to be 
Medicaid eligible 
• Children from families 
earning up to 200% of 
the federal poverty 
level 
• Federal Share: $14.4 
billion 
• State Share: $1.1 
billion (KFF, 2016) 
• 0.1% of GDP (KFF, 
2015)  
• State 
Veterans 
Affairs 
• Veterans who served in 
active military, navy, 
air force, current or 
former Reserves 
servicemen or National 
Guard officers called to 
active duty 
• Covers those with a 
service related 
disability, low income 
or low net worth 
veterans, or other 
circumstances, as 
applicable   
• Does not cover 
dishonorable 
discharges 
• FY 2015: $61 billion 
(Tax Policy Center, 
2015)  
• Federal 
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2.2 PORTUGAL 
Portugal’s system is inspired by the Beveridge national health service model (Lopez-
Casasnovas, Maynou, & Saez). Their health care system is much like the National Health System 
in the United Kingdom, called the Portuguese Servico Nacioal de Saúde, or SNS (NHS choices), 
and began in the late 1970s. All citizens are covered under public insurance plans. Then citizens 
can opt into purchasing private insurance, which is usually used for services with long waitlists 
in the SNS, including specialist care (Cabral).  
Private and public health care are still options in Portugal’s system today. Competition 
between private and public health care does exist. Multidisciplinary teams, called Family Health 
Units (USF) were created (Oliveira). Under the reform, the SNS is funded through a combination 
of the National Health Service, taxes, and government funding (Oliveira). There are three major 
medical access points: primary care facilities, and two forms of family health units (USF) which 
are multidisciplinary groups who provide primary care for patients (Oliveira). 
2.3 SPAIN 
In Spain’s 1978 Constitution, it was determined that health care is a basic right for all 
citizens. All citizens have “equal access to preventive, curative, and rehabilitative services” 
(Borkan, Eaton, Novillo-Ortiz, Cotre, Jadad). Spain, with its universal health care system, spends 
about half as much of its GDP on healthcare, compared to the United States, with under 10% and 
encroaching 20%, respectively (Borkan, Eaton, Novillo-Ortiz, Cotre, Jadad). Spain utilized 
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primary care teams to promote prevention and overall health (Borkan, Eaton, Novillo-Ortiz, 
Cotre, Jadad,).  
The Universal Health Care funding is provided through mandatory taxation. All citizens 
are covered under the public system. Primary care options offer disease prevention, health 
promotion, preventative care, and education to stay healthy (Borkan, Eaton, Novillo-Ortiz, Cotre, 
Jadad). Spain’s healthcare system is set up and managed by region, which are administrative 
divisions compared to the states within the United States, but with less autonomy and legislative 
power. In addition to the national health system, Spaniards are able to purchase private insurance 
as a supplemental option (Borkan, Eaton, Novillo-Ortiz, Cotre, Jadad). Primary Care Physicians 
are able to refer patients to all specialists if necessary. Under the national health system, patients 
are not allowed to make appointments with specialists without a PCP referral. Individuals with 
private insurance are able to see these specialists quicker because they are able to surpass the 
wait time (Rocha, et.al.). 
Similar to the United States, primary Care Physicians are able to provide detection and 
diagnosis, treatment, and counseling on Mental Health. If they are unable to find a solution, the 
patient is referred to a specialist. Private insurance allows a patient to skip the waiting period 
under publically funded insurance to see specialists (Rocha, et. al.). 
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3.0  AN ANALYSIS OF THE OPIOID CRISIS 
3.1 THE UNITED STATES 
One of the causes of the opioid epidemic in the U.S is the overprescribing of pain 
medications. The overprescribing of opioids originally exposes a high proportion of individuals 
to opioids, which are highly addictive substances, often leading to addiction, and eventually the 
need to switch to cheaper, and easier to obtain street drugs, like heroin. Overdose deaths have 
reached a serious toll, even beginning in the early 2000s, “The rate increased on average by 10% 
per year from 1999 to 2006, by 3% per year from 2006 to 2014, and by 18% per year from 2014 
to 2016” overdose death rates increased by over 30% (CDC). Honor R. Gil Kerlikowske states in 
the transcript from the Hearing Before the Subcommittee on Crime and Terrorism of the 
Committee on the Judiciary United States Senate, in May of 2011:  
Prescription drug abuse is the fastest-growing drug problem in the United States. 
It is categorized as a public health epidemic by the Centers for Disease Control 
and Prevention. The number of individuals who for the first-time consumed 
prescription drugs for non-medical purpose was similar to the number of first-
time marijuana users. We have also seen a fourfold increase in addiction 
treatment admissions for individuals primarily abusing prescription painkillers 
from 1997 to 2007 (U.S Congress).  
 
Honor Sherrod Brown states, “Education about the threat of prescription drugs is more difficult 
because these legal drugs have an important medical purpose, are prescribed by physicians, and 
come from pharmacies. Teens are too often unaware of the dangers of misuse and abuse” (U.S 
Congress). 
Many states began using prescription drug monitoring programs, also known as PDMPs, 
mandates the provider to record the prescribed drugs, and the pharmacies to record what they 
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have dispensed to each patient; the issue is that all regulations are not the same across states. The 
implementation of PDMPs have reduced the instances of doctor shopping, due to reporting. The 
use of PDMPs have also reduced the likelihood of fake or tampered prescriptions (CDC).  In 49 
states prescribers and pharmacists are able to access PDMPs. Currently, PDMPS offer interstate 
sharing of prescription/dispensing data in real time, Health Information Exchange (HIE) 
incorporation, included in Standard of Care, unsolicited reports, standardization, and an increase 
in the authorized users of the program (Brandies University). 
Law enforcement officials are able to access PDMPs in 47 states, while providers 
offering substance abuse treatment have access in only 12 states (SAMHSA). Substance abuse 
treatment providers should have access to PDMPs to review the medications that their patients 
have been on. These can act as medical history tools, and can likely help with an understanding 
of where a patient’s addiction has begun. Arguably, it is equally important for substance abuse 
providers to have this access over law enforcement.  
PDMPs are great intrastate systems that have provided a reactionary measure on the 
opioid crisis. 70% of the states that use PDMPs implemented them between 2000-2010 as a 
reactive measure to the opioid crisis. These systems need to have synergy across the nation.   
The Centers for Disease Control has provided recommendations regarding PDMPs. For 
optimal use, prescribers should check the system before prescribing a controlled substance, 
pharmacists should record the prescription at the time of dispense, health departments should 
utilize data within the system to recognize hot spot areas, and regular updates should be 
incorporated to allow the system to be easy to use. Additionally, PDMP data can be used to 
prevent future addiction cases in patients. The system can allow coroners to complete accurate 
toxicology testing. Other positive aspects to the system include increasing education, creating 
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prevention programs, and promote safe prescribing. If PDMPs were used as a national system, 
surveillance programs can be implemented across states, and the most comprehensive models 
can be utilized (CDC).  
Despite the need to change and improve PDMPs, especially across state borders, they 
have made an impact on the opioid crisis. In the beginning of the crisis, opioids prescribed for 
pain by physicians were largely responsible for addiction, because of their potency. By 2015, 
illicit substances, like heroin, were equally as responsible for the opioid crisis, as prescribed 
medications were. This transition shows the changes in prescribing practices, and likely the 
implementation and utilization of systems like PDMPs (CDC). 
The 2011 Obama administration constructed a four-prong plan to combat the astonishing 
numbers of misuse of drugs. This plan includes provider and patient education upon prescribing, 
PDMPs for every state, guidelines for medication discarding, and law enforcement improvement 
(NIH).  
Good Samaritan laws exist within each state to protect individuals against legal trouble 
for helping another person who is experiencing an overdose. These laws vary from state to state; 
Regarding possession of an illicit substance, individuals who seek medical or legal services are 
protected against arrest in 18 states, charges in 25 states, prosecution in 35 states, and affirmative 
defense in 2 states (Law Atlas). Good Samaritan Laws are vitally important in this epidemic, 
because they can assist in preventing fatal overdoses. A person would likely be more inclined to 
call emergency services about an overdose if they know they it will not result in getting in legal 
trouble.  
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3.2 PORTUGAL 
Portugal is at the forefront of overcoming the opioid crisis through the success of legal 
changes, with a success rate showing they have among the lowest death rates caused by drug 
overdoses in Europe (Cabral). In 2015, Portugal’s overdose death rate was 5.8 deaths per million, 
while a majority of European countries had an average rate of 20.3 deaths per million 
(EMCDDA). In addition, in 2001, Portugal made the policy move to decriminalize obtaining, 
using, and having small quantities psychoactive drugs in one’s possession (Laqueur). 
Continually, Portugal decriminalized civil acts pertaining to use, obtainment, and possession of 
psychoactive drugs (Laqueur). Prior to the move toward decriminalization, there was legislature 
calling for disease treatment instead of punishment (Laqueur), in turn, positively effecting the 
stigma surrounding drug use. Drug misusers are not seen as criminals any longer. The stigma has 
changed by shifting the connection of drug use and criminal acts, to drug use and a disease that 
can be addressed through treatment. Outcomes were positive, in that more people sought 
treatment and less people were dying from an overdose (NHS). There were nearly 27,000 
patients who sought outpatient treatment facilities and about 4,600 who utilized inpatient 
treatment in 2015 (EMCDDA). 
The decriminalization eased the legal system by keeping people out of jail and 
transitioning them into treatment centers. Additionally, Portugal has reported national spending 
in both legal and health care industries related to drugs to decrease, by more than 15%, between 
the years of 2000-2010 (Goncalves and Nogueria da Silva). Portugal has become a model for 
other countries to observe, as well as strive to make similar changes.  
Portugal has a Commissions for the Dissuasion of Drug Addiction, which exists in each 
district. The Commission is a Committee board that acts as an advisory board with the ability to 
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determine if someone who is caught with more than an allotted amount of a drug should be 
criminally charged, fined, or allow the individual to seek treatment. They essentially play the 
role of the court system. Under the Commissions, physicians are able to report patients that they 
may believe are using drugs (Laqueur). 
Even before decriminalization, many individuals caught using drugs were not sentenced 
to prison (Laqueur). Regardless of the possibility of no prison sentence, “before 
decriminalization, addicts were afraid to seek treatment because they feared that would be 
denounced to the police and arrested, now they know they will be treated as patients with a 
problem and not stigmatized as criminals” (Laqueur). After the 2001 change, further strides 
occurred; most of the penalties for being caught did not include fines (Laqueur), and did not 
include prison time. Portugal saw the number of patients seeking treatment increased by almost 
10,000 patients from 2001 to 2008, at just over 29,000 to 38,000 respectively (Laqueur). 
Portugal recognized that there was a significant drug use problem in their country, and further 
established that the best way to promote change was to change the culture. Positive outlooks and 
intelligent partnerships, complete with warm handoffs, or easy transition, between law 
enforcement and medical professionals promoted one of the best turn arounds seen in this 
epidemic. The culture change allowed individuals who use drugs to seek peer help. Encouraging 
behavior and outlooks among communities can plant the initial desire for help in overcoming 
misuse. Seeing individuals addicted to drugs can also discourage others from beginning 
recreational use. 
Portugal offers Syringe and Needle Exchange Programs, which were originally 
implemented in response to the spread of HIV/AIDs. These programs are mainly implemented 
through mobile clinics, in hotspot areas throughout the country. The exchange program was 
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created in partnership with local pharmacies (Soares, et. al.). This intervention provided a 
positive impact for both the spread of HIV/AIDS, and drug use.  
3.3 SPAIN 
Spain, unlike the negative trend seen in the United States, and the positive trend seen in 
Portugal, has seen a stagnant trend with drug use. Spain has offered a middle ground in the 
comparison of the three countries. It has been reported that Spain has remained somewhat 
consistent in regards to drug usage among its population, as the trends proved to be stable over 
recent years. 
Heroin use is the main substance reported, the trend of high heroin use has remained 
stable among users. Trends have decreased from 2010-2013, and then remained stable between 
the reporting years of 2013 and 2014 (EMCDDA). Heroin is responsible for a majority of 
negative health consequences from drug use. The average age of first use in Spain is 24 years 
old. The average age of first time treatment is 38 years old. Gender differences among heroin 
users are quite significant, 14% are female and 86% are male (EMCDDA). Smoking heroin is 
the most prevalent method of use at nearly 80%, which surpassed injection in popularity in the 
1990s. There was an observed decline in use between 2000 to 2003. A trend increase was 
reported beginning in 2004, which again, continued to stay constant (Barrio, et. al.).  
Spain has clearly identified the current drug use trends, where they are occurring, and with which 
drug they are occurring most often. Additionally, they have treatment options in place, and 
should be pushing for a more positive outcome, instead of staying the same. Furthermore, Spain 
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offers clean needle and syringe programs, safe injection sites, and Naloxone programs in the 
hotspot areas (EMCDDA).   
3.4 LAWS TO COMBAT THE OPIOID CRISIS 
The below analysis accounts for all 50 states, plus the District of Columbia. To combat 
the number of drug overdose deaths, many states decided to implement protective laws, 
including two addressed in this analysis: Good Samaritan Laws and Naloxone Access Laws. 
Often, these two laws are unknown or misunderstood by the population, though they were 
implemented to positively impact the crisis (SAMHSA). Several states have implemented both 
laws as a reaction to the crisis, in order to save the lives of individuals overdosing on drugs.  
Good Samaritan laws protect individuals who assist others in medical and emergency 
situations, like a drug overdose. This means often means that the individual reporting the 
overdose will not be arrested, charged, or prosecuted, for calling in the emergency. Many states 
have conditional protections. 37 states in the U.S have implemented various Good Samaritan 
laws, pertaining to an overdose situation, 14 states are lacking these laws. Various states offer 
some or all of the following protections from arrest, charge, and/or prosecution pertaining to 
controlled substance possession, drug paraphernalia possession, probation or parole violations, 
and reporting an overdose becoming a mitigating factor in sentencing (PDAPS). Table 2 below 
provides detailed information on the ten states classified in the five highest and five lowest 
overdose death rates between 2000 and 2015. 
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Table 2: Good Samaritan Laws for States By Overdose Deaths Rates 
Drug 
Overdose 
Death 
Rates 
2005 
Drug 
Overdose 
Death 
Rates 
2016 
Rate 
increase 
from 
2005-
2016 
State Good 
Samaritan 
Law 
Protection 
from 
Controlled 
Substance 
Protections 
from Drug 
Paraphernalia  
Protections 
from 
probation 
or parole 
violations 
Reporting 
an OD as 
mitigating 
factor in 
sentencing  
9 11.2 2.2 CA Yes Arrest, 
Charge, 
Prosecution 
Arrest, 
Charge, 
Prosecution 
No No 
7.5 30.8 23.3 DE Yes Arrest, 
Charge, 
Prosecution 
Arrest, 
Charge, 
Prosecution 
Yes No 
9.1 11.1 2 KS No No Data  No Data No Data No Data 
10.1 11.7 1.6 MT No No Data  No Data No Data No Data 
5 6.4 1.4 NE No No Data  No Data No Data No Data 
10.7 39 28.3 NH Yes Arrest, 
Prosecution 
None No No 
10.9 39.1 28.2 OH Yes Arrest, 
Charge, 
Prosecution 
None Yes No 
13.2 37.9 24.7 PA Yes Charge, 
Prosecution 
Charge, 
Prosecution 
Yes No 
13 14.5 1.5 WA Yes Charge, 
Prosecution 
None No Yes 
10.5 52 41.5 WV Yes Prosecution None Yes Yes 
 
 
Delaware, New Hampshire, Ohio, Pennsylvania, and West Virginia have the largest rate 
increases of overdose deaths between the years of 2005 and 2016; all of the rate increases fall 
between 23.3-41.5 per 100,000 of the total population (CDC). These five states all have some 
form of Good Samaritan laws set up, Table 3 details each state’s Good Samaritan laws. Delaware 
and Ohio’s laws protect against arrest, charge, and prosecution from possession of controlled 
substances. New Hampshire prevents the individual assisting from arrest and prosecution; 
Pennsylvania defends against charge and prosecution, and West Virginia only protects against 
prosecution. The Good Samaritan laws in New Hampshire, Ohio, and West Virginia all fail to 
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defend against drug paraphernalia possession. Pennsylvania protects against charge and 
prosecution. Lastly, Delaware has the most protective set up in place from drug paraphernalia, 
with arrest, charge, and prosecution.  New Hampshire is the only state in the top five death rate 
increases that lacks protections from probation or parole violations. West Virginia is the only 
state in this group that allows reporting an overdose as a mitigating factor in sentencing 
(PDAPS). West Virginia, with the least amount of protections, should offer improvements for 
their citizens. I hypothesize that increase protections would offer a decrease in the amount of 
drug overdose deaths. One major barrier, as discussed, is the population’s understanding of their 
protections. Increased protections will offer decreased preventable overdose deaths. 
Table 3: Good Samaritan Laws 
Good Samaritan Law 
California Cal. Health & Safety Code § 
11376.5 
Medical assistance for controlled 
substances/paraphernalia possession, and 
related offenses for those experiencing an 
overdose, there are no exceptions to laws 
prohibiting sales, forcible administration, or 
liability for controlled substance use; 
Despite any other laws, it is not considered a 
crime to be under the influence, or have 
possession of a controlled substance, or drug 
paraphernalia if an individual calls emergency 
services, with good intentions, for another person 
who is experiencing an overdose, no other 
immunities from arrest or prosecution are 
allowed; 
Despites any other law, it is not a crime for a 
person, who is experiencing and overdose, to be 
under the influence of, or in possession of 
controlled substances if they need medical 
attention, and another person at the scene calls 
for help, no other protections are permitted; 
This section does not affect other laws banning 
the selling/distributing, or forcing another person 
to take drugs against their will; 
This section does not affect liability for offenses 
whole under the influence of a controlled 
substance, but does not limit violations of the 
vehicle code 
Delaware Del. Code. Tit. 16, § 4769 Criminal immunity for individuals who are 
experiencing, or report, an overdose, or life 
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threatening emergency.  
An individual who contacts medical services for 
an overdose will not be arrested, charged, 
prosecuted, or changed or revoked parole, if: 
they report in good faith, provide relevant 
information on the cause of the overdose, at the 
scene or at the medical facility; 
Immunity applies to miscellaneous drug crimes, 
illegal possession or delivery of non-controlled 
medications, possession of controlled substances 
or counterfeit, possession of drug paraphernalia; 
This section's information should not be 
interpreted to be applied in other offenses that do 
not apply directly to this section.  
New 
Hampshire 
N.H. Rev. Stat. § 318-B:28-b Immunity from liability 
A person who calls for medical attention, in good 
faith and in a timely manner, for an overdose, will 
not be arrested, prosecuted, or convicted for 
possessing a controlled substance if found at the 
scene; 
This section should not be interpreted to 
decrease admissibility of evidence at the scene 
for another person who does not fall under these 
protections; 
Contraband can be seized by law enforcement; 
Law enforcement can arrest and hold anyone 
who does not fall under these protections. 
Pennsylvania 35 Pa Cons. Stat. §780-113.7 A person is immune from charge, prosecution, or 
parole violation if: law enforcement is made 
aware of the situation from the person 
transporting someone experiencing an overdose 
to a law enforcement station, campus police, or 
health care facility; the overdose is reported in 
good faith; they provide their name, location, and 
cooperate with law enforcement; they remain at 
the scene 
The person who overdosed is immune if the 
person reporting remains present 
Banning charges or prosecution is limited to the 
following:  
This section may not bar charges or prosecution 
if law enforcement becomes aware of the 
information prior to, or independent of the 
individual calling for law enforcement assistance; 
this section cannot interfere with the 
investigation, arrest, charging or prosecution of 
distributing controlled substances, or causing a 
drug induced homicide: this section cannot ban 
the acceptability of evidence related to a crime 
not illustrated in these sections; this section 
cannot restrict the use of evidence of an 
investigation of a crime with another defendant 
whom of which does not fall under these 
protections; if an individual who is subject to 
prosecution, that falls under immunity is 
Table 3 Continued 
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prosecuted, they are not responsible for the civil 
liability for filing the charges. 
Washington Wash. Rev. Code § 69.50.315  An individual with sincere intensions, who calls 
for medical assistance to aid a person 
undergoing a drug induced overdose, will not be 
charged or prosecuted for having a controlled 
substance in their possession.  
Those experiencing an overdose, needing 
medical assistance, will not be charged for 
possessing a controlled substance. 
The protections offered will not be used against 
them regarding other crimes.  
West Virginia W. Va. Code § 16-47-4 A person whom, in good faith, reports an 
overdose in a timely manner will not be criminally 
responsible of: possessing alcohol under the age 
of 21; providing fake identification to obtain 
alcohol; purchasing or consuming alcohol and 
unintoxicating beer under age 21;knowingly, and 
intentionally possessing a controlled substance; 
appearing intoxicated in public, drinking liquor in 
public; drinking in a motor vehicle on a highway, 
roadway, or parking garage; possessing liquor 
made under violations. 
Immunity does not apply to: selling or serving 
alcohol or liquor by someone under 21 years old. 
Immunity applies to: the person who reports the 
overdose stays with the person until medical 
services arrive; they identify themselves to law 
enforcement upon reporting the overdose; they 
cooperate, providing information to law 
enforcement, or emergency services; reporting 
an overdose may act as a mitigating 
circumstance upon criminal sentencing in 
prosecuting, where immunity does not apply. 
Given that the sentencing was because of 
evidence obtained or behavior during the 
reporting of the overdose;  
Despite the opposing, a person following the law 
who gets charged with an offense not exempt 
under this section, may plead guilty after 
consulting with their attorney; immunities that fall 
under civil law may not hold true to criminal law; 
a person who requests assistance, following this 
section, is not in violation of conditions regarding 
pretrial release, probation, leave, or parole. 
W. Va. Code § 16-47-5 Immunities outline in Section 4 apply to the 
person whom medical services were called for, 
as long as the person participates and completes 
a treatment plan provided by the court. If not, the 
court can consider the following: deferred 
prosecution; pretrial diversion; judgement in 
court; alternative sentencing or treatment 
including: probation, conditional discharge; 
weekend jail, work programs, community service; 
Table 3 Continued 
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regardless of contradictory guidelines, a person 
who tries to gain immunity, but is charged, can 
plea guilty to an offense after consulting with their 
attorney. 
W. Va. Code § 16-47-6 Law enforcement is immune from civil 
responsibilities for citing or attesting an individual 
who is layer found to fall under immunities, 
except in cases of deliberate misconduct. 
California, Kansas, Montana, Nebraska, and Washington have the lowest overdose death 
rate changes between 2005 and 2016; all of the rate increases are between 1.4-2.2 per 100,000 of 
the total population (CDC). Three of the bottom 5 states, Kansas, Montana, and Nebraska, have 
no data listed on protections from controlled substances, drug paraphernalia, probation or parole 
violations, or reporting an overdose to act as a mitigating factor in sentencing. Washington and 
California both have Good Samaritan laws in place. California’s laws protect from arrest, charge, 
and prosecution of individuals who have controlled substances and from drug paraphernalia in 
their possession. Washington’s laws protect against charge and prosecution of possessing a 
controlled substance; there are no protections in place drug paraphernalia possession, nor from 
probation or parole violations. 
Additionally, all of these states have a Naloxone Access Law in place. These laws 
provide protections similar to those of Good Samaritan Laws. None of the above listed states 
have civil liability immunity for a prescriber as it pertains to prescribing, dispensing, and 
distributing Naloxone (PDAPS). Refer to Table 4 for detailed information on Naloxone Access 
Laws.  
Table 3 Continued 
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Naloxone laws can allow Naloxone prescriptions to be authorized to third parties, 
pharmacies can dispense/distribute Naloxone without a patient specific prescription, and a 
layperson can be immune to criminal and civil liabilities for administering Naloxone. Pharmacies 
are able to dispense/distribute Naloxone without a patient specific prescription in all ten states 
listed, except Nebraska. Delaware is the only state that does not provide criminal liability 
immunity to those laypeople who administer Naloxone. Delaware, Nebraska, and Ohio do not 
provide civil liability immunities to laypeople administering naloxone.  
Naloxone access laws can provide protections for physicians, pharmacists, third parties, 
and laypeople. Each of the 50 states, plus D.C, have naloxone access laws set up. Good 
Samaritan laws may directly affect Naloxone laws, because the protections of Good Samaritan 
laws can determine if a peer or bystander is willing to help save someone who is experiencing 
and overdose instead of fleeing the scene.  
Table 4: Naloxone Access Laws 
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Good Samaritan Laws and Naloxone Laws can aid in the change of drug misuse stigma. 
Portugal can be used as an example. Implementing these laws are can protect people who would 
call emergency services or administer naloxone in someone overdosing, they would be more 
likely to help that person. The ultimate challenge exists with informing the population as a whole 
of these two laws, and the protects they offer to encourage helping others in good faith. 
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4.0  RECOMMENDATIONS 
• Increase the general population’s knowledge and educational opportunities about drug 
facts, addiction, risk factors, overdoses, and Naloxone administration. 
• Develop a change management program to shift the general population’s stigma on drug 
misusers, and those addicted to drugs. 
• Create partnerships between law enforcement, the mental health system, and treatment 
facilities for individuals that are in need of help through the use of a universal database. 
• Implement clean needle sharing programs, especially in hot spot areas. 
• Increase access to treatment centers through expansion of services to include inpatient 
and outpatient services, that are customized subjectively, and embody and holistic 
approach.  
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5.0  CONCLUSION 
Each of the three countries have taken their own steps to decrease the occurrences of 
overdose deaths, and to prevent children and teens from becoming addicted to opioids and illicit 
drugs. Portugal was able to change both policies and the stigma that surround drug use. They 
have seen a voluntary uptake of people seeking treatment programs of all forms, and there has 
been a decrease in the number of young people misusing drugs.  Spain has been able to provide 
clean needle and syringe programs, safe injection spaces, and Naloxone dispensing for overdose 
cases. 
Stigma describes the rejection of society on drug users. Stigma convinces drug users that 
they will be rejected and looked down upon, so they tend to keep use to themselves (Palamar). 
Cocaine and opioid drug users experienced high levels of rejection (Palamar). Fear and stigma 
prohibit treatment seeking (Palamar, Hakitis, & Kiang). There are three intervention techniques 
in changing stigmas, which include, protesting the unfair treatment of individuals, education to 
provide actual facts, and contact with people facing addiction (Michaels, et. al). Increasing 
knowledge about drugs, risk factors, overdoses, and Naloxone administration can be an effective 
way to begin the change in stigma in the U.S. Increasing education may allow for individuals to 
seek treatment, or to prevent overdose deaths in peers (Espelt, et. al.). This recommendation can 
work in the U.S, and can be utilized through many different avenues, including television, radio, 
advertisements, continuing educational credits, and mandatory courses at all school levels. It is 
important for this education to be administered at all ages because the epidemic is so widespread 
throughout the U.S. Between the years of 2013 and 2014, all regions of the U.S saw increases in 
overdose deaths. The northeast recorded an 8.8% increase, Midwest had a 9.6% increase, the 
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south’s deaths increased by 6.9%, and finally the west showed a 0.7% increase. Additionally, 
between 2013 and 2014, all age groups saw an increase in deaths, including children ages 0-14, 
with 105 and 109 deaths, respectively. The age groups of 25-34 and 35-44 years old saw the 
largest percent increases, at 10.5 and 8.7%. Knowing the signs and risk factors of addictive drugs 
can allow fewer lives to be lost, and increased seeking in treatment (CDC).  
Education, addressing several working parts of the opioid crisis, is necessary in changing 
the stigma of drug users by Americans. As addressed in the analysis section, much of the 
American population is unaware of protective laws that states have implemented in response to 
the crisis. People do not understand, or are completely unaware of Good Samaritan and 
Naloxone Access laws. Educating the general public seems like an easy first step in saving the 
lives of others, as well as introducing a change in stigma. 
There are many people that are unaware of underlying causes of addiction, and the 
impacts that mental health has on an individual. Chemically and physiologically, opioids have a 
high addiction potential, due to their potency, so it is normal for people who are prescribed these 
medications to become addicted. Additionally, it needs to be common knowledge that mental 
health and addiction often go together, and those individuals need to have access to healthcare 
for treatments. Several individuals who suffer from addiction also experience mental illnesses, 
including depression and anxiety. Mental illnesses can be as a result of addiction, or addiction 
begins to deal with mental illnesses (NIH). Mental Health needs to be taken more seriously. 
Until education is expanded, and a basic understanding of Mental Health needs are addressed, 
the stigma will not change.  
As a pilot location to test educational programs, Pennsylvania’s Allegheny County 
houses the southwestern portion of the state’s only syringe exchange program, called Prevention 
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Point Pittsburgh. This program provides clean syringes to discourage the spread of HIV and 
Hepatitis C. Other services include counseling, education, and case management on disease 
spread prevention, naloxone education and how to use it, high risk behavior education, HIV 
wound care, and STI testing. The aforementioned services are all provided anonymously for all 
individuals who seek them. There are three locations that patients can seek services from, most 
of which are located in low income areas. One of the locations is a physical building, located in 
Pittsburgh’s neighborhood of East Liberty. The program also provides three mobile clinic 
locations, on three different a week, at various locations throughout the city. Since Prevention 
Point Pittsburgh was created to help drug users, this group could be an excellent target to ask 
their opinions on educational materials, like brochures and pamphlets.  
Creating partnerships between entities like law enforcement, mental health professionals, 
and treatment facilities will greatly impact the opioid epidemic. A partnership will encourage 
proper treatment, and another chance at life for those addicted to drugs. The success of this 
partnership would reach many individuals in all areas of the U.S. This will success will not 
currently work, because the importance of Mental Health is so underestimated. Until it is 
recognized, getting people help will be difficult. Drug misusers should not be placed in jail, 
because that will offer no solution to them, nor the criminal system.  
The implementation of a program, like PDMPs, would create a universal system that can 
be shared by law enforcement, mental health, and treatment professionals. A universal system 
provides the opportunity to share data across disciplines. This system would in the least provide 
information on individuals, and can help in providing the best care and next steps for them. This 
should be a universal system that works beyond stateliness, to be the most effective. 
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Syringe and needle exchanges should be available in hot spot areas of the states, as they are in 
Portugal. Pennsylvania’s Allegheny county has implemented a program that can be translated to 
other hot spot areas. Prevention Point Pittsburgh’s model can act as an example for a safe needle 
exchange program in Allegheny County. A needle exchange portion can be added to their 
already provided programs. This model can be used in other cities throughout the United States. 
Due to the model working within the United States already, it would be a more realistic 
recommendation then implementing a program used in other countries, like Portugal and Spain. 
These two countries are able to provide syringe and needle exchange programs through mobile 
clinics in hotspot areas around the country. An additional barrier that the United States faces is 
jurisdiction laws. Providing needle and syringe exchange programs may be illegal because it can 
be classified as providing drug paraphernalia to users. Government officials can be ordered “to 
look the other way” in response to the laws surrounding these exchange programs (Burris, 
Finucane, Gallagher, & Grace). Realistically, all jurisdictions within the United States need to 
have law enforcement “look the other way” to implement successful programs, like those in 
Spain and Portugal.   
In 2014, nearly 23 million people were in need of addiction treatment services, of that 23 
million, only about 4 million people were able to receive treatment, and even less, about 2.6 
million people were able to seek specialized treatments (NIH). Treatment options need to be 
customizable for each individual seeking treatment. Each person is unique, meaning that a 
blanket treatment program may not work for everyone. Treatment plans should change with the 
individual as they go through their perspective treatment programs (NIH). A holistic approach 
will allow several health aspects to be addressed. Treatment options that have shown to be 
successful include behavioral health therapy, medication assisted therapies, devices and 
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applications to teach skills to overcome withdrawal symptoms, simultaneous treatment of mental 
illnesses, and follow-up to avoid relapsing (NIH). 
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